American pharmaceutical giant Pfizer Inc. (NYSE: PFE) is boosting its hematology drug pipeline with the acquisition of Global Blood Therapeutics (NASDAQ: GBT) in a $5.4 billion all-cash deal. How Does the Deal Benefit Pfizer? Global Blood Therapeutics is a clinical-stage biopharmaceutical company with a focus on discovering drugs to treat rare blood disorders. Its very first drug Oxbryta® (voxelotor) tablets, was approved in 2019 for the treatment of sickle cell disease (SCD), which is a life-threatening inherited blood disorder affecting people mainly of African, Middle Eastern, and South Asian descent. Notably, Oxbryta contributed $195 million in sales in 2021 and $55.2 million in the first quarter of 2022.
https://www.tipranks.com/news/pfizer-boosts-drug-pipeline-with-global-blood-therapeutics-acquisition?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Set 2022 até Out 2022 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Out 2021 até Out 2022 Click aqui para mais gráficos Pfizer.